COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,796 Articles (22,527 medRxiv, 8,269 bioRxiv)

Most recent first Previous |  Page 203: Articles 2021-2030  | Next

The Global Impact of COVID-19 on Tuberculosis: A Thematic Scoping Review, 2020-2023
Marco, M. H., Ahmedov, S., Castro, K. G.
10.1101/2024.03.04.24303743 — Posted: 2024-03-06
Mental illness and COVID-19 vaccination: a multinational investigation of observational & register-based data
Barker, M. M., Koiv, K., Magnusdottir, I., Milbourn, H., Wang, B., Du, X., Murphy, G., Herweijer, E., Gisladottir, E. U., Li, H., Lovik, A., Kahler, A. K., Campbell, A., Feychting, M., Hauksdottir, A., Joyce, E. E., Thordardottir, E. B., Frans, E., Hoffart, A., Magi, R., Tomasson, G., Asbjornsdottir, K., Jakobsdottir, J., Andreassen, O., Sullivan, P., Johnson, S. U., Aspelund, T., Brandlistuen, R. E., Ask, H., McCartney, D. L., Ebrahimi, O. V., Lehto, K., Valdimarsdottir, U., Nyberg, F., Fang, F.
10.1101/2024.03.05.24303691 — Posted: 2024-03-06
Targeting G9a translational mechanism of SARS-CoV-2 pathogenesis for multifaceted therapeutics of COVID-19 and its sequalae
Muneer, A., Xie, L., Xie, X., Zhang, F., Wrobel, J., Yan, X., Yu, X., Wang, C., Gheorghe, C., Wu, P., Song, J., Ming, G.-L., Jin, J., Song, H., Shi, P.-Y., Chen, X.
10.1101/2024.03.04.583415 — Posted: 2024-03-06
MORTALITY-ASSOCIATED SARS-COV-2 GENOMIC VARIANTS FROM PATIENTS HOSPITALIZED FOR SEVERE PNEUMONIA IN AGUASCALIENTES, MEXICO FROM 2020 TO 2023
Gomez, B. M., Gamboa, M. L., Marmolejo, A. P., Ceapa, C. D.
10.1101/2024.03.05.583594 — Posted: 2024-03-06
Regulation of virion production by the ORF8 signal peptide across SARS-CoV-2 variants
Khalid, M. M., Chen, I., Soveg, F. S., Taha, T. Y., Tabata, T., Suryawanshi, R., Syed, A. M., Ciling, A., McCavitt-Malvido, M., Schulze-Gahmen, U., Hayashi, J., Kim, I.-J., Fong, S. W., Batra, J., Kumar, G. R., Laurent, R., NG, L. F., Krogan, N. J., Doudna, J. A., Verdin, E., Ott, M.
10.1101/2024.03.05.583578 — Posted: 2024-03-06
Molecular hydrogen for outpatients with Covid-19 (Hydro-Covid): a phase 3, randomised, triple-blinded, adaptive, placebo-controlled, multicentre trial
GABOREAU, Y., Milovancev, A., Rolland, C., Eychenne, C., Alcaraz, J.-p., Ihl, C., Mazet, R., Boucher, F., Vermorel, C., Ostojic, S. M., Borel, J. C., Cinquin, P., Bosson, J.-L.
10.1101/2024.02.23.24303304 — Posted: 2024-03-05
The Majority of SARS-CoV-2 Plasma Cells are Excluded from the Bone Marrow Long-Lived Compartment 33 Months after mRNA Vaccination
Nguyen, D. C., Hentenaar, I. T., Morrison-Porter, A., Solano, D., Haddad, N. S., Castrillon, C., Lamothe, P. A., Andrews, J., Roberts, D., Lonial, S., Sanz, I., Lee, F. E.-H.
10.1101/2024.03.02.24303242 — Posted: 2024-03-05
Yeast-based production platform for potent and stable heavy chain-only antibodies
Lonigro, C., Eeckhaut, H., Symakani, R. A., Roose, K., Schepens, B., Sedeyn, K., De Smet, A.-S., Zavala Marchan, J. C., Vanhaverbeke, P., Vanmarcke, S., Claes, K., De Cae, S., Demol, H., Devos, S., Fijalkowska, D., Nerinckx, W., Rossey, I., Weyts, W., Abdelnabi, R., Jochmans, D., Neyts, J., Saelens, X., van Schie, L., Callewaert, N.
10.1101/2024.03.04.580093 — Posted: 2024-03-05
A 10-valent composite mRNA vaccine against both influenza and COVID-19
Wang, Y., Ma, Q., Li, M., Mai, Q., Ma, L., Zhang, H., Zhong, H., Cheng, N., Feng, P., Guan, P., Wu, S., Zhang, L., Dai, J., Zhang, B., Pan, W., Yang, Z.
10.1101/2024.03.05.583547 — Posted: 2024-03-05
Why is the Omicron main protease of SARS-CoV-2 less stable than its wild-type counterpart? A crystallographic, biophysical, and theoretical study of the free enzyme and its complex with inhibitor 13b-K
Ibrahim, M., Sun, X., de Oliveira, V. M., Liu, R., Clayton, J., El Kilani, H., Shen, J., Hilgenfeld, R.
10.1101/2024.03.04.583178 — Posted: 2024-03-05

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).